AIDA EXPANDS DRUG PIPELINE WITH THREE DRUGS

China's Aida Pharmaceuticals has expanded its drug development pipeline with the acquisition of three new drugs -- one with potential to treat immune disorders and two anticancer drugs. The addition of these new drugs swells Aida's product pipeline from four to seven developmental drugs. The three drugs are either being evaluated for pre-clinical trials or in various early stages of applied research. Pharmaceutical Business Review (http://www.pharmaceutical-business-review.com/article_news.asp?guid=F192D1AD-A82A-47E4-A3DD-D4E361A5832F)